Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder of the pluripotent stem cell resulting from the somatic mutation of the X-linked PIG-A gene, involved in the synthesis of the glycosylphosphatidyl-inositol (GPI) anchor of membrane proteins such as CD55, CD59 and CD14. In the past decade, flow cytometry has become a valuable diagnostic tool in the detection of deficient expression of the GPIanchored proteins. We report the diagnosis of PNH in four patients confirmed by flow cytometry. Red blood cells, granulocytes and monocytes were classified as PNH types I, II and III according to the mean fluorescence intensities (MFI) of membrane proteins. The MFI rate is a numerical data reflecting the severity of decreased antigen expression, and it is obtained by dividing the MFI of the type II or type III cells by the MFI of the respective cells obtained for a normal sample. We found that the investigation of granulocytes and monocytes was more informative than red blood cells when percent negativity was evaluated. In addition, the lowest MFI rate (mean 0.011) was obtained for CD14 on monocytes while CD59 and CD55 gave higher values on all three investigated cell types (0.021-0.34). Thus, CD14 on monocytes seems to be the most reliable marker for establishing the PNH clone size and the severity of antigen deficiency.
eral membrane proteins, such as CD55 (decay accelerating factor), CD59 (membrane inhibitor of reactive lysis) and CD14 (lipopolysaccharide receptor), also known as a monocyte marker wreviewed in Ref. (4)x. Mutation of the PIG-A gene aborts synthesis of the GPI-anchored proteins on the surface of erythrocytes, leukocytes and platelets (5) . Recently it was verified that clonal populations of hemopoietic cells with PNH genotype and phenotype are present in normal bone marrow samples (6, 7) . The development of PNH requires the simultaneous presence of two factors: the mutated stem cells and an abnormal, hypoplastic bone marrow environment (8, 9) . The relative growth advantage of the PNH clone in patients is partly explained by the fact that non-mutant stem cells from PNH bone marrow have a higher apoptotic rate than PIG-A mutant stem cells, resulting in the clonal expansion of the mutant clone in the hostile marrow environment (10, 11) . Alternatively, the PIG-A mutation might confer a relative advantage to PNH clones over normal cells. This theory is also supported by current experimental data indicating that PIG-A mutant cells are relatively resistant to cytotoxic attack by natural killer cells and cytotoxic T-lymphocytes (12, 13) . Due to the increased susceptibility of red blood cells (RBC) to complement-mediated lysis, the leading clinical symptoms are nocturnal hemolysis and morning hemoglobinuria (14) . The pathophysiology of other clinical signs, like immune-mediated bone marrow failure and thrombotic tendency are not fully elucidated (15) . Despite the lack of membrane-bound CD14, monocytes from PNH patients can respond to bacterial lipopolysaccharides through an activation pathway dependent on soluble CD14, present in normal amounts in their sera (16) (17) (18) .
Before the widespread use of flow cytometric assays, PNH patients with hemolysis were diagnosed with the Ham test (19) and the sucrose test (20) . These tests rely on the differential sensitivity of PNH red blood cells to hemolysis after the activation of the complement system. In the past decade, flow cytometry has emerged as a valuable diagnostic tool in the detection of deficient expression of the GPIanchored proteins in PNH patients (21) (22) (23) (24) (25) (26) (27) . The advantage of flow cytometry is, that even in nonhemolysing patients, small PNH clones can be detected and the proportion of type III (complete deficiency), type II (partial deficiency) and type I (normal) cells in each investigated population can be determined (23) (24) (25) (26) .
We tried to find reliable numerical data characterizing the severity of GPI-anchored protein deficiency In the period of January 2001 to December 2004, 80 samples were analyzed in our laboratory from patients with clinical evidence of hemolysis, and the diagnosis of PNH could be confirmed by flow cytometry in only four cases. In the medical history of these patients, several episodes of abdominal pain with vomiting, dark urine, fever and back pain could be explored. Detailed examinations could not detect malignancy or ulceration in the gastrointestinal tract and bone marrow examination showed minimal dysplastic alteration without signs of neoplasia. Laboratory tests displayed anemia, elevated lactate dehydrogenase (LDH) activity, unconjugated hyperbilirubinemia, low haptoglobin and high reticulocyte percentage measured after attacks (Table 1) . Hemolysis was evident and a positive sucrose test suggested the possibility of PNH.
Venous blood samples from patients and healthy controls were collected into K 3 EDTA-containing tubes for whole blood count (Technicon H3 hematology analyzer, Bayer Diagnostics, Tarrytown, NY, USA) and for flow cytometric analysis (FACScan flow cytometer, Becton Dickinson, San Jose, CA, USA). For RBC analysis, whole blood was diluted with phosphate-buffered saline (PBS) and the RBC count was set to 1=10 7 /mL. One hundred mL diluted blood was mixed with 5 mL phycoerythrin-conjugated anti-CD55 or anti-CD59 (both from Pharmingen, San Diego, CA, USA) monoclonal antibody. After a 30-min incubation at room temperature in the dark, cells were centrifuged at 300=g for 5 min and the pellet was resuspended in 1 mL PBS. After the second wash, the pellet was resuspended in 0.5 mL 1% paraformaldehyde (PFA).
For granulocyte and monocyte analysis 50 mL blood was mixed with a saturating concentration of phycoerythrin-conjugated anti-CD55 or anti-CD59 or anti-CD14 (Becton Dickinson) monoclonal antibody. After a 15-min incubation period at room temperature, 1 mL BD lysing solution at working dilution was added to each tube. Samples were incubated for 10 min and then centrifuged for 5 min at 300=g. The pellet was resuspended in 1 mL PBS and after the second washing step the cells were resuspended in 0.5 mL 1% PFA. PE-conjugated mouse IgG 1 was used as negative control. Granulocytes and monocytes were analyzed from their respective gates created in the forward and side scatter dot plots. Cells were classified as PNH I, PNH II and PNH III according to their mean fluorescence intensities. In the case of CD55 and CD59 on RBCs, granulocytes and monocytes were classified as PNH III when MFI was below 10, PNH II when MFI was 34"11 and PNH I when MFI was 280"150. In the case of CD14 on monocytes, type III cells had MFI 39"36, no type II cells were found and type I cells had MFI 2060"1000, in accordance with the higher CD14 antigen number on monocytes. Quantitative measurements were performed using Quantibrite beads (Becton Dickinson) according to the instructions of the manufacturer. The number of PE molecules bound per cell was calculated from the MFI of the unknown cell population using a calibration curve created from given values for PE molecules per bead plotted against FL2 MFI. Monoclonal antibodies in this study were monovalent and the PE:mAb ratio was 1:1; this was the basis of the antibody binding capacity (ABC) calculation.
The characteristic histograms of a normal and a PNH granulocyte population are shown in Figure 1 . The result report contains the MFI of the CD55-or CD59-deficient -type II or type III cells separatelyand the normal cell population together with the percent of the negative cells ( Figure 1B and Table 2 ). The average of the percent negative cells in the case of RBCs was one third of that obtained in the case of granulocytes and monocytes. This phenomenon is well known in PNH patients and can be explained by the premature destruction of these PNH erythrocytes. The size of the PNH clone can be better assessed by immunophenotypic analysis of monocytes and granulocytes rather than of erythrocytes (26, 28) .
However, these report forms do not express the heterogenous expression of the GPI-anchored proteins when compared to a normal cell population. We recommend a new parameter, the MFI rate, which can be obtained by dividing the MFI of the PNH type II or PNH type III cells by the MFI of the respective cell population obtained for the normal sample ( Figure  1C) . In all four cases, the expression of CD55 and CD59 on the remnant normal cell population (PNH type I), represented by the MFI value, was similar to that of the normal sample ( Figure 1A) . The smaller the MFI rate, the better the discrimination between the GPI-negative and the normal cells can be achieved. Our results are in accordance with previous reports (21) describing that anti-CD55 does not delineate the erythrocyte population as well as anti-CD59 does. This finding is evidenced numerically by the calculation of MFI rates, being much lower for CD59 (0.011-0.031 in four different patients) than for CD55 (0.049-0.096 respectively) in erythrocytes. Although molecular biological techniques are extremely sensitive in the detection of PIG-A mutations, the transiently detected mutant clones in healthy individuals (5, 6) indicate that these clones have no selective advantage in a normal marrow environment and PNH is not manifested. Flow cytometry is now the laboratory investigation of choice.
Besides the percent negative cell ratio in each population, we report the MFI rates that provide more information about the decreased antigen expression of PNH cells compared to normals. Furthermore, in the case where the patient has PNH type II and type III cells at the same time ( Table 2 , patient 4), the MFI rate can be calculated separately for the appropriate populations. We found this approach reliable and cost-effective, while the use of REDQUANT and CELL-QUANT assays only provide another degree of confidence for the differentiation of normal and PNH cells (29, 30) . According to the literature, quantitative analysis of CD55 and CD59 on normal blood cells gave Besides red blood cells, granulocytes and monocytes, we detected lower expression of CD55 and CD59 on lymphocytes and platelets as well, but that was not informative concerning clone size and severity of antigen deficiency. It has been previously shown in PNH patients that monocytes have the lowest expression of GPI-anchored molecules (34) . We also found that the most informative cell type for the detection of GPI-negative cells is the monocyte population, because the CD14 expressing and nonexpressing cells can be easily separated, as indicated by the lowest MFI rates (0.007-0.015 determined in four different patients). Thus, we recommend reporting the CD14-negative monocyte percent along with the MFI rate in order to determine the PNH clone size and the severity of antigen deficiency on the cell surface, respectively.
Another application of flow cytometry is in the detection of small PNH clones, like in aplastic anemia (35) . Flow cytometry can also be used after CAM-PATH-1H therapy in the detection of PNH-like lymphocytes (36) . In these cases flow cytometry is the only method for the follow-up of the small clone size and the calculation of the MFI rate would be an extra data in the diagnosis and monitoring of patients.
In conclusion, a novel, calculated parameter, the MFI rate, is a numerical data reflecting the severity of decreased antigen expression. Based on MFI rate results, monocyte CD14 seems to be the most valuable marker in the determination of PNH clone size.
